Civ1 inhibitors (sanofi-aventis)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameCiv1 inhibitors (sanofi-aventis)
Drug Alias NameCiv1 inhibitors (Aventis)Civ1 protein kinase inhibitor (Aventis)RU-319
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase modulators
TargetsCyclin-dependent kinase
Therapy Area/IndicationsCandida Albicans InfectionsMycoses
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAventis Pharma Sa
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSanofiAventis Pharma Sa
Active IndicationsN/A
Inactive IndicationsCandida Albicans InfectionsMycoses

Other Information

ATC CodeN/A
Related LinksN/A